Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL
Clinical Summary:
- Design/Population: The phase 3 SUNMO trial randomized transplant-ineligible patients with relapsed/refractory large B-cell lymphoma to receive subcutaneous mosunetuzumab plus polatuzumab vedotin or rituximab plus gemcitabine/oxaliplatin, including patients treated in the second-line and later-line settings.
- Key Outcomes: Mosunetuzumab plus polatuzumab vedotin continued to improve progression-free survival and response rates, with consistent benefit in both second-line and third-line or later subgroups.
- Clinical Relevance: Mosunetuzumab plus polatuzumab vedotin may provide an effective, chemotherapy-sparing option, with particularly notable activity in the second-line setting and a favorable immune-toxicity profile.
Elizabeth Budde, MD, PhD, City of Hope Comprehensive Cancer Center, Durante, California, discusses updated results from the phase 3 SUNMO trial which demonstrated that mosunetuzumab plus polatuzumab vedotin continues to provide superior efficacy compared with rituximab, gemcitabine, and oxaliplatin among transplant-ineligible patients with relapsed/refractory large B-cell lymphoma.
Dr Budde presented these results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Kim W, Westin J, Maruyama D, et al. Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroup. Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. 7007.
